Carroll Stuart C, Gaskin Brent J, Goldberg Ivan, Danesh-Meyer Helen V
Department of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Clin Exp Ophthalmol. 2006 Apr;34(3):213-8. doi: 10.1111/j.1442-9071.2006.01196.x.
To summarize current practice styles and patterns associated with glaucoma management in ophthalmologists of Australia and New Zealand as derived from a survey.
A questionnaire was sent to all Australian and New Zealand ophthalmologists, which anonymously assessed demographic characteristics and prescribing patterns for each major class of glaucoma medication.
A total of 761 questionnaires were sent with a response rate of 51%. Of respondents 14% were glaucoma subspecialists. In 69%, the first-line drug-class of choice was a prostaglandin analogue. New Zealand ophthalmologists favoured beta-blockers as their first-line agent because of cost, government restrictions and familiarity. Most respondents stated "hypotensive efficacy" as the most important factor in class choice. Alpha-2-agonists, carbonic anhydrase inhibitors and miotics were considered second-line agents, because of side-effects and lack of hypotensive potency.
The choice of first-line agent for the treatment of glaucoma differed between Australian and New Zealand ophthalmologists, in part as the result of government restriction of prostaglandin-class drugs. Practice patterns seen in Australasia parallel the current evidence base reported in peer-reviewed literature.
总结一项调查得出的澳大利亚和新西兰眼科医生青光眼治疗的当前实践方式和模式。
向所有澳大利亚和新西兰眼科医生发送了一份问卷，匿名评估了人口统计学特征以及各类主要青光眼药物的处方模式。
共发送了761份问卷，回复率为51%。在受访者中，14%是青光眼专科医生。69%的人首选的一线药物类别是前列腺素类似物。由于成本、政府限制和熟悉程度等原因，新西兰眼科医生更倾向于将β受体阻滞剂作为一线药物。大多数受访者表示“降压效果”是药物类别选择中最重要的因素。由于副作用和降压效力不足，α₂激动剂、碳酸酐酶抑制剂和缩瞳剂被视为二线药物。
澳大利亚和新西兰眼科医生在青光眼治疗一线药物的选择上存在差异，部分原因是政府对前列腺素类药物的限制。在澳大拉西亚地区观察到的实践模式与同行评审文献中报道的当前证据基础相符。
